Latest News and Press Releases
Want to stay updated on the latest news?
-
TORONTO, Sept. 27, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) a product-focused biopharmaceutical company developing...
-
TORONTO, Sept. 24, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Monday, September 27, 2010 at 4:30 P.M....
-
Clinical Study of TT-223 in Combination With a GLP-1 Analogue Does Not Meet Study Efficacy Endpoints
TORONTO, Sept. 17, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) announced today that a clinical study of gastrin analogue TT-223 in...
-
TORONTO, June 30, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) announced today that the first patient has been dosed with drug...
-
TORONTO, June 7, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer...
-
TORONTO, May 10, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH), a product-focused biopharmaceutical company developing therapeutics...
-
TORONTO, May 10, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Tuesday, May 11, 2010 at 8:30 A.M. EDT to...
-
TORONTO, March 3, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. (TSX:TTH) (Nasdaq:TTHI) today announced that it has acquired the rights to a series of preclinical compounds from Eli Lilly and...
-
TORONTO, Feb. 25, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer...
-
TORONTO, Feb. 10, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI), a product-focused biopharmaceutical company developing therapeutics for...